Viewpoints in clinical proteomics: when will proteomics deliver clinically useful information?
Despite massive efforts, proteomics has not delivered biomarkers of clinical value. However, the technologies that are emerging today have the power to reach deep into proteomes and identify the patterns associated with different diseases. Study design is then crucial and sample quality, bioinformatics approaches, prevalidation, using independent patient cohort need to attract increased attention before proteomics will contribute to the needs of personalized medicine.
Department of Immunotechnology & CREATE Health Translational Cancer Center, Lund University, BMC D13, Lund, Sweden. carl.borrebaeck@immun.lth.se
Carl A K
CA
Borrebaeck
D000465:Algorithms; D015415:Biomarkers / Q000378:metabolism; D030562:Databases, Protein; D006801:Humans; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results; D057170:Translational Research, Biomedical
D015415:Biomarkers